hVIVO’s order book has more than doubled to £65 million, prompting Shore Capital to reiterate its Buy rating and 25p target price.
hVIVO Orderbook More Than Doubles as Commercial Momentum Rebuilds
hVIVO said its orderbook has more than doubled in the first half of 2026, supported by strong commercial momentum and higher proposal activity.
Avacta cuts convertible bond debt with £3.67m payment
Accelerated Amortized Payment of Convertible Bond Installment
Avacta Appoints Patrick Vink as Deputy Chairman
Avacta Therapeutics (AIM: AVCT) has appointed healthcare executive Dr Patrick Vink to its board as non-executive deputy chairman and senior independent director.
Avacta advances AVA6000 towards pivotal US trial
Avacta Therapeutics (AIM: AVCT) has secured a significant regulatory milestone after reaching an agreement with the US Food and Drug Administration on the pivotal trial design for its lead cancer
Shareholders give overwhelming support to Avacta proposals
Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.
Avacta Extends Cash Runway as Clinical Pipeline Advances
Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of
£9m fundraising gives Avacta extra firepower for cancer pipeline
Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting
Avacta showcases progress in salivary gland cancer study
Avacta Group PLC (AIM: AVCT) unveiled encouraging new clinical data for its lead oncology candidate AVA6000 (faridoxorubicin) at the ASCO 2026 annual meeting, highlighting both promising efficacy and a potentially
Avacta Therapeutics (AIM: AVCT) Board Director Changes
Avacta Therapeutics (AIM: AVCT) has announced a boardroom transition, with Richard Hughes to be appointed non-executive chairman following the company’s Annual General Meeting on 22 June 2026.
Avacta strengthens cancer treatment story with clinical advances
Avacta Group plc has reported significant progress across its pre|CISION oncology platform in its unaudited preliminary results for the year ended December 31, 2025, as the company advances multiple cancer
Avacta Therapeutics (AIM: AVCT) Pre|CISION® payload release vs approved ADCs
Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026